Thoughts for a Sunday - Part 33 May 2020 18:33
In the RNS issued on the 28th June 2019, regarding the results of the General Meeting, that, and I quote, “London, UK., 28 June 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
Consequently, the Company affirmed that the authority relating to share capital allocation that they had requested in the “Notice of General Meeting” had been passed, on the basis requested.
In the RNS dated the 14th October 2019, in relation to a further fund raising which culminated in 310,769,231 shares being issued, and I quote, “ Following Admission, the Company's enlarged issued share capital will comprise 1,334,827,184 ordinary shares of 0.1p each with voting rights.”
This issue in itself isn’t perhaps noteworthy, but it does give us a confirmed share quantity in issue that will substantiate numbers being detailed in the next RNS.
In the RNS dated the 6th January 2020, which related to yet another placing, the following was highlighted.
The placing would culminate in an additional 200,000,000 shares being issued, and that following that issue the total number of shares in issue would be, and I quote, “Following Admission, the Company's enlarged issued share capital will comprise 1,534,827,184 ordinary shares of 0.1p each with voting rights.”
There are a number of other issues to discuss with regards to this RNS, particularly so relating to warrants, but firstly let us discuss the shares in issue.
That being that the addition of 200,000,000 shares to the previously notified shares in issue being 1,334,827,184 does indeed equate to the number of shares being in issue post the admission of these 200,000,000 shares scheduled for the 10 January 2020, to be then 1,534,827,184, therefore corroboration exists.
Hold on for a minute though, this statement from the Company, that states on the 10th January 2020 that 1,534,827,184 shares will be in issue, yet that is at odds with the maximum number permissible in authorisation (as detailed in the Notice of General Meeting) of 1,505,258,764.
Granted, in relation to over 1.5 billion shares in issue, this additional 29,568,420 shares which the Company state they have issued in excess of their legal authority to do so does not amount to a hill of beans.